---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-281213"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:06:46.103071+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Soleno reports Q3 2022 net loss of $6.1M; initiates randomized withdrawal of DCCR study for PWS

## Summary
- Cash at Sep 30, 2022: $19.8M; sufficient to fund operations through H1 2023 top-line data.
- Net loss Q3 2022: $6.1M ($0.76 per share) vs $8.1M ($1.53) YoY.
- R&D expense decreased to $3.8M from $5.0M YoY; G&A down to $2.3M.
- Initiated randomized withdrawal period of Study C602 for DCCR in PWS; top-line data expected H1 2023.
- FDA acknowledged that data from the study could support NDA submission.

## SEC filing metadata
- accession: 0001193125-22-281213
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312522281213/0001193125-22-281213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312522281213/d417158d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-281213
- JSON: https://secwatch.observer/filing/0001193125-22-281213.json
- Plain text: https://secwatch.observer/filing/0001193125-22-281213.txt

## Key facts
- Earnings Releases
  SOLENO THERAPEUTICS INC reported the three and nine months ended September 30, 2022 results: net income Net loss for the three and nine months ended September 30, 2022, was $6.1 million and $18.6 million, or a net loss of $0, EPS a net loss of $0.76 and $2.60 per basic and diluted share.
  - Period: the three and nine months ended September 30, 2022
  - Net income: Net loss for the three and nine months ended September 30, 2022, was $6.1 million and $18.6 million, or a net loss of $0
  - EPS: a net loss of $0.76 and $2.60 per basic and diluted share
  - Result: reported results
  source text: Soleno Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312522281213/0001193125-22-281213-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.